Incyte Analyst Ratings

Benzinga12:59 ET

Argenx Price Target Raised to $547.00/Share From $543.00 by Wells Fargo

Dow JonesJul 26 10:32 ET

Jefferies Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $598

Moomoo NewsJul 26 09:32 ET

A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $497 to $598

Moomoo NewsJul 26 09:04 ET

Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $81

Moomoo NewsJul 26 08:38 ET

Argenx Analyst Ratings

BenzingaJul 26 07:32 ET

Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125

Moomoo NewsJul 26 05:34 ET

Argenx Se (ARGX) Gets a Hold From UBS

TipRanksJul 26 04:56 ET

Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200

Moomoo NewsJul 26 03:32 ET

Buy Rating Affirmed: Argenx Se's Financial Success and Clinical Promise

TipRanksJul 26 02:04 ET

JMP Securities Sticks to Their Buy Rating for Argenx Se (ARGX)

TipRanksJul 25 14:42 ET

Wells Fargo Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $547

Moomoo NewsJul 25 07:34 ET

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Argenx Se (ARGX)

TipRanksJul 25 06:50 ET

JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $27

Moomoo NewsJul 25 00:32 ET

Exelixis Buy Rating Affirmed on Q2 Outperformance and Positive Litigation Outlook

TipRanksJul 25 00:27 ET

Oppenheimer Upgrades Argenx to Outperform, Cites Vyvgart Hytrulo

Seeking AlphaJul 24 10:47 ET

Outperform Rating With Raised Price Target for Revolution Medicines Amid Promising Oncology Trials

TipRanksJul 24 01:57 ET

Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen

Dow JonesJul 23 13:12 ET

Regeneron Pharmaceuticals Analyst Ratings

BenzingaJul 23 13:06 ET

Argenx Analyst Ratings

BenzingaJul 23 10:43 ET